Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease

References

• McPherson M, Economidou S, Liampas A, Zis P, Parperis K. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum. 2022;53(4):151959. doi:10.1016/j.semarthrit.2022.151959
   PubMedGoogle Scholar
• Takanashi S, Kaneko Y, Takeuchi T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: a literature review. Mod Rheumatol. 2022;32(1):231–237. doi:10.1080/14397595.2021.1906505
   PubMed Web of Science ®Google Scholar
• Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology. 2018;57(12):2114–2119. doi:10.1093/rheumatology/key188
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291–293. doi:10.1056/NEJMc1900045
   PubMed Web of Science ®Google Scholar
• Lamba M, Wang R, Fletcher T, Alvey C, Kushner J 4th, Stock TC. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol. 2016;56(3):1362–1371. doi:10.1056/NEJMc1900045
   PubMedGoogle Scholar
• Wang CR. Successful treatment of refractory juvenile dermatomyositis with Adalimumab. J Clin Rheumatol. 2017;23(3):174–175. doi:10.1097/RHU.0000000000000514
   PubMed Web of Science ®Google Scholar
• Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22(6):6338. doi:10.1097/BOR.0b013e32833f1970
   Web of Science ®Google Scholar
• Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49(3):43340. doi:10.1093/rheumatology/kep375
   Web of Science ®Google Scholar
• Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14(3):26474. doi:10.1093/rheumatology/kep375
   Web of Science ®Google Scholar
• Sun WC, Sun YC, Lin H, Yan B, Shi GX. Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol. 2012;167(6):123644. doi:10.1111/j.1365-2133.2012.11145.x
   Web of Science ®Google Scholar
• Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20(9):537–551. doi:10.1038/s41577-020-0288-3
   PubMed Web of Science ®Google Scholar
• Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology. 2014;53(12):2196–2203. doi:10.1093/rheumatology/keu258
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. doi:10.1038/nrrheum.2015.167
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(1):843–862. doi:10.1038/nrrheum.2015.167
   PubMedGoogle Scholar
• Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15–32. doi:10.1007/s40259-019-00333-w
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133–145. doi:10.1038/s41584-021-00726-8
   PubMed Web of Science ®Google Scholar
• Lamba M, Hutmacher MM, Furst DE, et al. Model-informed development and registration of a once-daily regimen of extended release tofacitinib. Clin Pharmacol Ther. 2017;101(6):745–753. doi:10.1002/cpt.576
   PubMed Web of Science ®Google Scholar
• Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(Suppl 1):i17–i26. doi:10.1093/rheumatology/key225
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Tanimura S, Matsumoto S, Nakamura H, Horita T. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis. Ann Rheum Dis. 2020;79(8):1125–1126. doi:10.1136/annrheumdis-2019-216606
   PubMed Web of Science ®Google Scholar
• Liu J, Hou Y, Sun L, et al. A pilot study of tofacitinib for refractory Behçet’s syndrome. Ann Rheum Dis. 2020;79(11):1517–1520. doi:10.1136/annrheumdis-2020-217307
   PubMed Web of Science ®Google Scholar
• Wang CR, Tsai YS, Liu YW, Li YH. Extended-release tofacitinib improves refractory Takayasu’s arteritis. Scand J Rheumatol. 2022;51(1):72–75. doi:10.1080/03009742.2021.1911054
   PubMed Web of Science ®Google Scholar
• Wang CR, Wong TW, Hsu SM. Extended-release tofacitinib for refractory Behçet disease: a case report. Medicine. 2022;101(15):e29189. doi:10.1097/MD.0000000000029189
   PubMed Web of Science ®Google Scholar
• Wang CR, Tsai HW. Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: a single-center retrospective study. World J Diabetes. 2022;13(6):454–465. doi:10.4239/wjd.v13.i6.454
   PubMed Web of Science ®Google Scholar
• Wang CR, Lin WC. Severe COVID-19 pneumonia in patients with rheumatoid arthritis under B-cell depletion therapy. J Formos Med Assoc. 2023;122(8):807–808. doi:10.1016/j.jfma.2023.03.002
   PubMedGoogle Scholar
• Ferrarini A, Vacca A, Solimando AG, et al. Early administration of tofacitinib in COVID-19 pneumonitis: an open randomized controlled trial. Eur J Clin Invest. 2023;53(2):e13898. doi:10.1111/eci.13898
   PubMed Web of Science ®Google Scholar